Please login to the form below

CD3

This page shows the latest CD3 news and features for those working in and with pharma, biotech and healthcare.

AstraZeneca acquires TeneoTwo in a deal worth up to $1.27bn

The agreement includes the acquisition of TeneoTwo’s phase 1 clinical-stage CD19/CD3 T-cell engager, TNB-486, which is currently being assessed in the treatment of relapsed and refractory

Latest news

Amgen pays $900m upfront to acquire Teneobio’s antibody assets, R&D technologies

In addition, the availability of Teneobio's CD3 engager technology will allow us to broaden our capabilities in generating bispecifics, and with our own technology, enable customisation of the T cell ... These three affiliates are developing an
Pfizer pauses enrolment for trial evaluating anti-BCMA bispecific antibody

The company announced the pause for the MagnetisMM-3 trial, which is evaluating the investigational BCMA CD3-targeted drug in patients with relapsed/refractory multiple myeloma, in its first quarter earnings
Lilly partners with Merus on development of bispecific antibodies for cancer

Eli Lilly has entered a research collaboration agreement with Dutch biotech Merus to develop CD3-engaging bispecific antibodies for the treatment of cancer. ... products. "CD3-engaging bispecific antibodies are rapidly becoming one of the most
Regeneron reveals first data for bispecific antibody in multiple myeloma

The antibody targets BCMA, a protein that is typically over-expressed on multiple myeloma cells, by binding to it and the CD3 receptor on T-cells, bringing them together and activating ... CD3 targeting bispecific antibody.
Sanofi’s new CEO cuts first deal, adding Synthorx for $2.5bn

Sanofi and Regeneron are also working on bispecific antibody immunotherapies, including two lead candidate targeting BCMA/CD3 and MUC/CD3, respectively.

More from news
Approximately 2 fully matching, plus 27 partially matching documents found.

Latest Intelligence

BiTE* platform and the evolution toward off-the-shelf immuno-oncology approaches

The reason the molecule is called ‘bispecific’ is that it is engineered from not one but two antibodies: one is designed to engage with CD3, which is found on T cells;
Taking a lean and careful approach

Its fully human engineered CD3 antibody Foralumab has reached phase II with potential for a wide range of autoimmune and inflammatory diseases such as non-alcoholic steatohepatitis (NASH), primary biliary cholangitis,
Deal Watch June 2016

Both antibodies have a cytotoxic T-cell binding domain (CD3), which activates T-cells at the site of the tumour for killing of malignant cells, and a specific tumour antigen binding
Pharma deals during December 2014

platform. The antibody targets both CD19 and CD3 and is being developed for the treatment of B-cell malignancies.
Deal Watch table for August 2014

187. Emergent BioSolutions/ Morphosys. Licence, joint development &commercialisation. MOR209/ES414, anti-PSMA/anti-CD3 bi-specific antibody targeting prostate cancer (preclinical).

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

Dr Kunwar Shailubhai appointed CEO of Tiziana Life Sciences

Shailubhai takes the helm as Tiziana focuses on developing an orally administered, anti-CD3 mAb (foalumab) drug candidate to manage non-alcoholic steatohepatitis (NASH) - a liver disease that has no treatment